Comparison Overview

Farmácia Saúde

VS

AUROBINDO PHARMA LTD

Farmácia Saúde

C.C. Atlantico, E.Leclerc, L7 Tavarede Figueira da Foz, Portugal 3080-510, PT
Last Update: 2025-03-15 (UTC)
Between 800 and 900

Strong

The Pharmacy existed since 1960, currently occupying a space about 500 m2. In this space the user can find specific areas for various types of care (semi-private, private and offices), for convenience. It has two exhibition spaces of orthopedic products, two private offices attending where you can perform analysis and specific tests, laboratory fully equipped for handling medicines, training room, etc. We are constantly perform scientic and academic work to improve our skills. It is our duty to make available to users of all new knowledge in public health.

NAICS: 325
NAICS Definition:
Employees: 11-50
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

AUROBINDO PHARMA LTD

Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, Telangana 500032, IN
Last Update: 2025-05-17 (UTC)

Strong

Between 800 and 900

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 25 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company’s robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Antiretroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,001+
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/farmacia-saude.jpeg
Farmácia Saúde
ISO 27001
Not verified
SOC 2
Not verified
GDPR
No public badge
PCI DSS
No public badge
https://images.rankiteo.com/companyimages/aurobindopharma.jpeg
AUROBINDO PHARMA LTD
ISO 27001
Not verified
SOC 2
Not verified
GDPR
No public badge
PCI DSS
No public badge
Compliance Summary
Farmácia Saúde
100%
Compliance Rate
0/4 Standards Verified
AUROBINDO PHARMA LTD
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Farmácia Saúde in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for AUROBINDO PHARMA LTD in 2025.

Incident History — Farmácia Saúde (X = Date, Y = Severity)

Farmácia Saúde cyber incidents detection timeline including parent company and subsidiaries

Incident History — AUROBINDO PHARMA LTD (X = Date, Y = Severity)

AUROBINDO PHARMA LTD cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/farmacia-saude.jpeg
Farmácia Saúde
Incidents

No Incident

https://images.rankiteo.com/companyimages/aurobindopharma.jpeg
AUROBINDO PHARMA LTD
Incidents

No Incident

FAQ

Both Farmácia Saúde company and AUROBINDO PHARMA LTD company demonstrate a comparable AI risk posture, with strong governance and monitoring frameworks in place.

Historically, AUROBINDO PHARMA LTD company has disclosed a higher number of cyber incidents compared to Farmácia Saúde company.

In the current year, AUROBINDO PHARMA LTD company and Farmácia Saúde company have not reported any cyber incidents.

Neither AUROBINDO PHARMA LTD company nor Farmácia Saúde company has reported experiencing a ransomware attack publicly.

Neither AUROBINDO PHARMA LTD company nor Farmácia Saúde company has reported experiencing a data breach publicly.

Neither AUROBINDO PHARMA LTD company nor Farmácia Saúde company has reported experiencing targeted cyberattacks publicly.

Neither Farmácia Saúde company nor AUROBINDO PHARMA LTD company has reported experiencing or disclosing vulnerabilities publicly.

Neither Farmácia Saúde company nor AUROBINDO PHARMA LTD company has publicly disclosed detailed information about the number of their subsidiaries.

Neither Farmácia Saúde company nor AUROBINDO PHARMA LTD company has publicly disclosed the exact number of their employees.

Latest Global CVEs (Not Company-Specific)

Description

Formbricks is an open source qualtrics alternative. Prior to version 4.0.1, Formbricks is missing JWT signature verification. This vulnerability stems from a token validation routine that only decodes JWTs (jwt.decode) without verifying their signatures. Both the email verification token login path and the password reset server action use the same validator, which does not check the token’s signature, expiration, issuer, or audience. If an attacker learns the victim’s actual user.id, they can craft an arbitrary JWT with an alg: "none" header and use it to authenticate and reset the victim’s password. This issue has been patched in version 4.0.1.

Risk Information
cvss3
Base: 9.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:L
Description

Apollo Studio Embeddable Explorer & Embeddable Sandbox are website embeddable software solutions from Apollo GraphQL. Prior to Apollo Sandbox version 2.7.2 and Apollo Explorer version 3.7.3, a cross-site request forgery (CSRF) vulnerability was identified. The vulnerability arises from missing origin validation in the client-side code that handles window.postMessage events. A malicious website can send forged messages to the embedding page, causing the victim’s browser to execute arbitrary GraphQL queries or mutations against their GraphQL server while authenticated with the victim’s cookies. This issue has been patched in Apollo Sandbox version 2.7.2 and Apollo Explorer version 3.7.3.

Risk Information
cvss3
Base: 8.2
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:H/A:N
Description

A security vulnerability has been detected in Portabilis i-Educar up to 2.10. Affected by this vulnerability is an unknown functionality of the file /consulta-dispensas. Such manipulation leads to improper authorization. The attack may be launched remotely. The exploit has been disclosed publicly and may be used.

Risk Information
cvss2
Base: 6.5
Severity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
cvss3
Base: 6.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A weakness has been identified in Portabilis i-Educar up to 2.10. Affected is an unknown function of the file /module/Api/aluno. This manipulation of the argument aluno_id causes improper authorization. The attack may be initiated remotely. The exploit has been made available to the public and could be exploited.

Risk Information
cvss2
Base: 6.5
Severity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
cvss3
Base: 6.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A security flaw has been discovered in Tencent WeKnora 0.1.0. This impacts the function testEmbeddingModel of the file /api/v1/initialization/embedding/test. The manipulation of the argument baseUrl results in server-side request forgery. The attack can be launched remotely. The exploit has been released to the public and may be exploited. It is advisable to upgrade the affected component. The vendor responds: "We have confirmed that the issue mentioned in the report does not exist in the latest releases".

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X